Latest Share Purchase Plan News

Australian Strategic Materials has successfully raised A$13 million through an institutional placement, complementing an oversubscribed Share Purchase Plan to total nearly A$25 million. These funds will accelerate ASM’s metallisation expansion in the US and ramp up production at its Korean Metals Plant.

Wide Open Agriculture reports a remarkable 243% jump in cash receipts driven by soaring lupin protein sales and secures a strategic foothold in China through an exclusive distribution deal.

Miramar Resources invites eligible shareholders to participate in a $1 million Share Purchase Plan at a 20% discount, aiming to accelerate drilling at its promising 8 Mile gold prospect within the Gidji JV Project.

Strike Resources signals potential for an additional A$5 million capital raise through oversubscriptions, pending board approval, with new shares under Tranche 2 set to follow the Share Purchase Plan issuance.

Larvotto Resources has successfully raised $60 million in equity alongside a $105 million bond, fully funding the Hillgrove Antimony-Gold Mine development with production targeted for mid-2026.

QuickFee Limited reports a record A$7.2 million quarterly revenue, driven by strong US and Australian growth, alongside positive underlying profitability and a major refinancing.

FireFly Metals has identified 325 promising geophysical targets at its Green Bay copper-gold project in Newfoundland, using advanced airborne surveys, and is accelerating drilling with strong financial backing.

New Murchison Gold Limited has transitioned from explorer to producer with mining underway at its Crown Prince project, backed by a $12 million capital raise and promising high-grade drilling results.

Australian Strategic Materials has successfully closed an oversubscribed Share Purchase Plan, raising nearly A$12 million at a 20% discount to recent market prices.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

QPM Energy has successfully raised $7 million through an oversubscribed Share Purchase Plan, significantly exceeding its initial $2 million target to accelerate key gas power projects in Queensland.